Recently, the potential use of cellular and circulating miRNAs as biomarkers for AML diagnosis/prognosis, and as therapeutic targets has been widely explored, and many miRNAs were found to be associated with HDAC2 dysfunction in leukemia 13. The gene discussed is HDAC2; the disease is leukemia.